Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Insulin Glargine Alone on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria :~* Patient with type 2 diabetes mellitus (T2DM) diagnosed for at least 1 year before the screening visit, receiving 1 or 2 OADs that can be Biguanide,Thiazolidinedione (TZD), -Alpha-glucosidase-inhibitor (alpha-GI),Sodium glucose co-transporter 2 (SGLT2) inhibitor,Sulfonylurea (SU),Rapid-acting insulin secretagogue (Glinide),diphenyl-peptidase -4 inhibitor (DPP-4 inhibitor).~* Signed written informed consent.~Exclusion criteria:~* At the screening visit: Age \<20 years.~* At the screening visit: HbA1c \<7.5% or \>9.5%.~* At the screening visit: fasting plasma glucose (FPG) \>180 mg/dL (10.0 mmol/L).~* Pregnancy or lactation, women of childbearing potential with no effective contraceptive method.~* Use of oral or injectable glucose-lowering agents other than those stated during the inclusion criteria in the 3 months before the screening visit.~* Previous treatment with insulin (except for short-term treatment due to intercurrent illness including gestational diabetes at the discretion of the trial physician).~* Laboratory findings at the time of screening:~* Amylase and/or lipase: \>3 times the upper limit of the normal (ULN) laboratory range,~* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST): \>3 ULN,~* Calcitonin ≥20 pg/mL (5.9 pmol/L),~* Positive serum pregnancy test in female of childbearing potential.~* Contraindication to use of lixisenatide according to the local labeling. History of hypersensitivity to any Glucagon-Like Peptide-1 Receptor Agonists or to metacresol.~* Contraindication to use of insulin glargine according to local labeling. History of hypersensitivity to insulin glargine or to any of the excipients.~* Patient who has a severe renal function impairment with estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73 m\^2 or end-stage renal disease for patient not treated with metformin.~* Personal or immediate family history of medullary thyroid cancer (MTC) or genetic condition that predisposes to MTC (eg, multiple endocrine neoplasia syndromes).~* History of pancreatitis (unless pancreatitis was related to gallstones and cholecystectomy has been performed), pancreatitis during previous treatment with incretin therapies, chronic pancreatitis, pancreatectomy, stomach/gastric surgery.~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LixiLan (Type: EXPERIMENTAL): LixiLan (insulin glargine/lixisenatide) is injected subcutaneously (under the skin) once daily. Dose is individually adjusted.~Background therapy with OADs (except dipeptidyl-peptidase-4 inhibitor) should be continued during the treatment period.
- insulin glargine (Type: ACTIVE_COMPARATOR): Insulin glargine (HOE901) is injected subcutaneously (under the skin) once daily. Dose is individually adjusted.~Background therapy with OADs (except dipeptidyl-peptidase-4 inhibitor) should be continued during the treatment period.

Based on this trial design, predict the completion outcome and termination type (if applicable).